Editas Medicine Inc (EDIT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $334.92M
Last updated: Nov 17, 2026 at 11:05 AM ET
Editas Medicine Inc (EDIT) Stock Forecast
Analysts expect Editas Medicine (EDIT) to earn -$0.83 per share in the fiscal year ending Dec 31, 2026, on revenue of $29.39M. Of 13 analysts, 9 rate the stock Buy or Strong Buy, 2 Hold and 2 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 5 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 2.62, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 69% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 9 | 69.2% |
| Hold | 2 | 15.4% |
| Sell | 0 | 0.0% |
| Strong Sell | 2 | 15.4% |
- Consensus
- Hold
- Total analysts
- 13
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 32.5%.
- Fiscal year ending Dec 31, 2026
- -$0.83
- EPS consensus, revenue $29.39M
- Fiscal year ending Dec 31, 2027
- -$0.74
- EPS consensus, revenue $19.83M
- Next report
- Mar 8, 2027
- Confirmed, after the close
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.83 | -$0.95 to -$0.78 | 4 | $29.39M | $27.00M to $33.63M | 5 |
| Dec 31, 2027 | -$0.74 | -$0.84 to -$0.60 | 6 | $19.83M | $2.00M to $39.33M | 12 |
Quarterly Estimates
The EPS consensus falls from -$0.19 for the quarter ending Dec 31, 2026 to -$0.20 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.19 | -$0.27 to -$0.08 | 14 | $6.76M | $980000 to $21.00M | 14 |
| Mar 31, 2027 | -$0.20 | -$0.20 to -$0.20 | 1 | $3.13M | $500000 to $6.41M | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 11 upward and 2 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 5 | 1 |
| Fiscal year ending Dec 31, 2027 | 5 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
The EPS consensus for the fiscal year ending Dec 31, 2026 has held over the last 90 days.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.83 | -$0.83 | -$0.83 | -$0.83 | -$0.83 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.74 | -$0.75 | -$0.75 | -$0.75 | -$0.75 | N/A |
| Quarter ending Mar 31, 2027 | -$0.20 | -$0.30 | -$0.30 | -$0.30 | -$0.27 | N/A |
Frequently Asked Questions About EDIT
What is the EDIT stock forecast?
Consensus analyst estimates put Editas Medicine's EPS at -$0.83 for the fiscal year ending Dec 31, 2026, on revenue of $29.39M. The consensus rating from 13 analysts is Hold.
How do analysts rate EDIT stock?
Of 13 analysts covering Editas Medicine, 0 rate it Strong Buy, 9 Buy, 2 Hold, 0 Sell and 2 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from EDIT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.83, with estimates from -$0.95 to -$0.78 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.74, with estimates from -$0.84 to -$0.60 from 6 analysts.
What revenue do analysts expect from Editas Medicine next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $29.39M, with estimates from $27.00M to $33.63M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $19.83M, with estimates from $2.00M to $39.33M.
How many analysts cover EDIT?
13 analysts rate Editas Medicine stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
EDIT pages: Overview, Earnings, Forecast, Financials, Competitors